Skip to content

Clinical study of percutaneous endocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy

Clinical study of percutaneous endocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085244
Enrollment
Unknown
Registered
2024-06-03
Start date
2024-06-05
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Obstructive Cardiomyopathy

Interventions

one:Percutaneous Endocardial Septal Radiofrequency Ablation

Sponsors

Chinese Academy of Medical Sciences Fuwai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 18-80 with a clear diagnosis of hypertrophic obstructive cardiomyopathy; (2) Completed percutaneous endocardial septal radiofrequency ablation for at least six months; (3) Follow up has been completed.

Exclusion criteria

Exclusion criteria: (1) There is a lack of clinical data, making it impossible to collect relevant medical records.

Design outcomes

Primary

MeasureTime frame
all cause mortality;left ventricular outflow tract gradient;Interventricular septal thickness;Cardiovascular death;Chest pain, shortness of breath, palpitations, syncope and presyncope;New York Heart Function Classification (NYHA classification);

Secondary

MeasureTime frame
Transfer to cardiac surgery and other treatments;

Countries

china

Contacts

Public ContactJia Yuhe

Cardiac Arrythmia Center, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC

jiayuhejyh@163.com+86 137 0135 8427

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026